Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway

Valentina Sancisi, Greta Gandolfi, Moira Ragazzi, Davide Nicoli, Ione Tamagnini, Simonetta Piana, Alessia Ciarrocchi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Modifications in adhesion molecules profile may change the way tumor cells interact with the surrounding microenvironment. The Cadherin family is a large group of transmembrane proteins that dictate the specificity of the cellular interactions. The Cadherin switch that takes place during epithelial-mesenchymal transition (EMT) contributes to loosening the rigid organization of epithelial tissues and to enhancing motility and invasiveness of tumor cells. Recently, we found Cadherin-6 (CDH6, also known as K-CAD) highly expressed in thyroid tumor cells that display mesenchymal features and aggressive phenotype, following the overexpression of the transcriptional regulator Id1. In this work, we explored the possibility that CDH6 is part of the EMT program in thyroid tumors. We demonstrate that CDH6 is a new transforming growth factor-β (TGF-β) target and that its expression is modulated similarly to other EMT mesenchymal markers, both in vitro and in thyroid tumor patients. We show for the first time that CDH6 is expressed in human thyroid carcinomas and that its expression is enhanced at the invasive front of the tumor. Finally, we show that CDH6 is under the control of the transcription factor RUNX2, which we previously described as a crucial mediator of the Id1 pro-invasive function in thyroid tumor cells. Overall, these observations provide novel information on the mechanism of the EMT program in tumor progression and indicate CDH6 as a potential regulator of invasiveness in thyroid tumors.

Original languageEnglish
Article numbere75489
JournalPLoS One
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 13 2013

Fingerprint

transforming growth factors
cadherins
Transforming Growth Factors
Tumors
Epithelial-Mesenchymal Transition
Thyroid Gland
Neoplasms
Cells
transcription factors
neoplasms
transmembrane proteins
Cadherins
carcinoma
adhesion
epithelium
thyroid neoplasms
K cadherin
phenotype
neoplasm cells
Thyroid Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway. / Sancisi, Valentina; Gandolfi, Greta; Ragazzi, Moira; Nicoli, Davide; Tamagnini, Ione; Piana, Simonetta; Ciarrocchi, Alessia.

In: PLoS One, Vol. 8, No. 9, e75489, 13.09.2013.

Research output: Contribution to journalArticle

Sancisi, Valentina ; Gandolfi, Greta ; Ragazzi, Moira ; Nicoli, Davide ; Tamagnini, Ione ; Piana, Simonetta ; Ciarrocchi, Alessia. / Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway. In: PLoS One. 2013 ; Vol. 8, No. 9.
@article{087f513e8f4647b18a9b35382497a63a,
title = "Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway",
abstract = "Modifications in adhesion molecules profile may change the way tumor cells interact with the surrounding microenvironment. The Cadherin family is a large group of transmembrane proteins that dictate the specificity of the cellular interactions. The Cadherin switch that takes place during epithelial-mesenchymal transition (EMT) contributes to loosening the rigid organization of epithelial tissues and to enhancing motility and invasiveness of tumor cells. Recently, we found Cadherin-6 (CDH6, also known as K-CAD) highly expressed in thyroid tumor cells that display mesenchymal features and aggressive phenotype, following the overexpression of the transcriptional regulator Id1. In this work, we explored the possibility that CDH6 is part of the EMT program in thyroid tumors. We demonstrate that CDH6 is a new transforming growth factor-β (TGF-β) target and that its expression is modulated similarly to other EMT mesenchymal markers, both in vitro and in thyroid tumor patients. We show for the first time that CDH6 is expressed in human thyroid carcinomas and that its expression is enhanced at the invasive front of the tumor. Finally, we show that CDH6 is under the control of the transcription factor RUNX2, which we previously described as a crucial mediator of the Id1 pro-invasive function in thyroid tumor cells. Overall, these observations provide novel information on the mechanism of the EMT program in tumor progression and indicate CDH6 as a potential regulator of invasiveness in thyroid tumors.",
author = "Valentina Sancisi and Greta Gandolfi and Moira Ragazzi and Davide Nicoli and Ione Tamagnini and Simonetta Piana and Alessia Ciarrocchi",
year = "2013",
month = "9",
day = "13",
doi = "10.1371/journal.pone.0075489",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway

AU - Sancisi, Valentina

AU - Gandolfi, Greta

AU - Ragazzi, Moira

AU - Nicoli, Davide

AU - Tamagnini, Ione

AU - Piana, Simonetta

AU - Ciarrocchi, Alessia

PY - 2013/9/13

Y1 - 2013/9/13

N2 - Modifications in adhesion molecules profile may change the way tumor cells interact with the surrounding microenvironment. The Cadherin family is a large group of transmembrane proteins that dictate the specificity of the cellular interactions. The Cadherin switch that takes place during epithelial-mesenchymal transition (EMT) contributes to loosening the rigid organization of epithelial tissues and to enhancing motility and invasiveness of tumor cells. Recently, we found Cadherin-6 (CDH6, also known as K-CAD) highly expressed in thyroid tumor cells that display mesenchymal features and aggressive phenotype, following the overexpression of the transcriptional regulator Id1. In this work, we explored the possibility that CDH6 is part of the EMT program in thyroid tumors. We demonstrate that CDH6 is a new transforming growth factor-β (TGF-β) target and that its expression is modulated similarly to other EMT mesenchymal markers, both in vitro and in thyroid tumor patients. We show for the first time that CDH6 is expressed in human thyroid carcinomas and that its expression is enhanced at the invasive front of the tumor. Finally, we show that CDH6 is under the control of the transcription factor RUNX2, which we previously described as a crucial mediator of the Id1 pro-invasive function in thyroid tumor cells. Overall, these observations provide novel information on the mechanism of the EMT program in tumor progression and indicate CDH6 as a potential regulator of invasiveness in thyroid tumors.

AB - Modifications in adhesion molecules profile may change the way tumor cells interact with the surrounding microenvironment. The Cadherin family is a large group of transmembrane proteins that dictate the specificity of the cellular interactions. The Cadherin switch that takes place during epithelial-mesenchymal transition (EMT) contributes to loosening the rigid organization of epithelial tissues and to enhancing motility and invasiveness of tumor cells. Recently, we found Cadherin-6 (CDH6, also known as K-CAD) highly expressed in thyroid tumor cells that display mesenchymal features and aggressive phenotype, following the overexpression of the transcriptional regulator Id1. In this work, we explored the possibility that CDH6 is part of the EMT program in thyroid tumors. We demonstrate that CDH6 is a new transforming growth factor-β (TGF-β) target and that its expression is modulated similarly to other EMT mesenchymal markers, both in vitro and in thyroid tumor patients. We show for the first time that CDH6 is expressed in human thyroid carcinomas and that its expression is enhanced at the invasive front of the tumor. Finally, we show that CDH6 is under the control of the transcription factor RUNX2, which we previously described as a crucial mediator of the Id1 pro-invasive function in thyroid tumor cells. Overall, these observations provide novel information on the mechanism of the EMT program in tumor progression and indicate CDH6 as a potential regulator of invasiveness in thyroid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84884196738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884196738&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0075489

DO - 10.1371/journal.pone.0075489

M3 - Article

C2 - 24069422

AN - SCOPUS:84884196738

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e75489

ER -